Business Description
Syndax Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US87164F1057
Total Employee Number:
298Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.05 | |||||
Equity-to-Asset | 0.09 | |||||
Debt-to-Equity | 8.3 | |||||
Debt-to-EBITDA | -1.68 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.9 | |||||
Beneish M-Score | -0.92 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -6.5 | |||||
3-Year EPS without NRI Growth Rate | -10.2 | |||||
3-Year FCF Growth Rate | -19.3 | |||||
3-Year Book Growth Rate | -52.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 55.79 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.96 | |||||
9-Day RSI | 71.89 | |||||
14-Day RSI | 66.45 | |||||
3-1 Month Momentum % | -28.61 | |||||
6-1 Month Momentum % | -14.75 | |||||
12-1 Month Momentum % | 92.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.47 | |||||
Quick Ratio | 5.06 | |||||
Cash Ratio | 4.19 | |||||
Days Inventory | 963.47 | |||||
Days Sales Outstanding | 55.31 | |||||
Days Payable | 574.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.7 | |||||
Shareholder Yield % | -4.45 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 95.99 | |||||
Operating Margin % | -102.81 | |||||
Net Margin % | -111.88 | |||||
EBITDA Margin % | -94.59 | |||||
FCF Margin % | -127.94 | |||||
OCF Margin % | -127.94 | |||||
ROE % | -204.7 | |||||
ROA % | -43.58 | |||||
ROIC % | -300.3 | |||||
3-Year ROIIC % | -538.23 | |||||
ROC (Joel Greenblatt) % | -10694.1 | |||||
ROCE % | -45.44 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.8 | |||||
PB Ratio | 46.98 | |||||
Price-to-Tangible-Book | 46.98 | |||||
EV-to-EBIT | -9.44 | |||||
EV-to-Forward-EBIT | 16.01 | |||||
EV-to-EBITDA | -9.44 | |||||
EV-to-Forward-EBITDA | 15.92 | |||||
EV-to-Revenue | 8.93 | |||||
EV-to-Forward-Revenue | 5.33 | |||||
EV-to-FCF | -6.98 | |||||
| Price-to-Net-Current-Asset-Value | 49.07 | |||||
Earnings Yield (Greenblatt) % | -10.59 | |||||
FCF Yield % | -14.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SNDX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Syndax Pharmaceuticals Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 217.421 | ||
| EPS (TTM) ($) | -2.79 | ||
| Beta | 0.3853 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.43 | ||
| Volatility % | 79.37 | ||
| 14-Day RSI | 66.45 | ||
| 14-Day ATR ($) | 0.970413 | ||
| 20-Day SMA ($) | 19.463 | ||
| 12-1 Month Momentum % | 92.67 | ||
| 52-Week Range ($) | 8.585 - 25.59 | ||
| Shares Outstanding (Mil) | 88.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Syndax Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Syndax Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 16:30 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 28 days | ||
| R&D Day | 2026-07-14 08:30 | In 8 days | ||
| General meeting for 2026 | 2026-06-10 12:00 | 17.69 (+2.25%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 14:00 | 17.34 (-4.36%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 09:20 | 18.34 (-1.29%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit | 2026-05-27 13:00 | 19.90 (-0.45%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 16:30 | 20.63 (-1.72%) |
Show
Entries
Syndax Pharmaceuticals Inc Frequently Asked Questions
What is Syndax Pharmaceuticals Inc(SNDX)'s stock price today?
The current price of SNDX is $22.08. The 52 week high of SNDX is $25.59 and 52 week low is $8.59.
When is next earnings date of Syndax Pharmaceuticals Inc(SNDX)?
The next earnings date of Syndax Pharmaceuticals Inc(SNDX) is 2026-08-04 Est..
Does Syndax Pharmaceuticals Inc(SNDX) pay dividends? If so, how much?
Syndax Pharmaceuticals Inc(SNDX) does not pay dividend.
Guru Commentaries on NAS:SNDX
No articles.
Press Release
Articles on Syndax Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers